Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does BLINATUMOMAB Cause Therapy non-responder? 255 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 255 reports of Therapy non-responder have been filed in association with BLINATUMOMAB (BLINCYTO). This represents 2.8% of all adverse event reports for BLINATUMOMAB.

255
Reports of Therapy non-responder with BLINATUMOMAB
2.8%
of all BLINATUMOMAB reports
105
Deaths
14
Hospitalizations

How Dangerous Is Therapy non-responder From BLINATUMOMAB?

Of the 255 reports, 105 (41.2%) resulted in death, 14 (5.5%) required hospitalization, and 13 (5.1%) were considered life-threatening.

Is Therapy non-responder Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for BLINATUMOMAB. However, 255 reports have been filed with the FAERS database.

What Other Side Effects Does BLINATUMOMAB Cause?

Pyrexia (1,064) Acute lymphocytic leukaemia recurrent (977) Cytokine release syndrome (952) Off label use (590) Death (588) Neurotoxicity (530) Drug ineffective (345) Headache (335) Neutropenia (265) Febrile neutropenia (262)

What Other Drugs Cause Therapy non-responder?

ETANERCEPT (3,472) APREMILAST (3,360) METHOTREXATE (2,965) RITUXIMAB (2,731) ADALIMUMAB (2,595) PREDNISONE (2,563) TREPROSTINIL (2,289) INFLIXIMAB (2,122) TOCILIZUMAB (1,775) HYDROXYCHLOROQUINE (1,699)

Which BLINATUMOMAB Alternatives Have Lower Therapy non-responder Risk?

BLINATUMOMAB vs BLONANSERIN BLINATUMOMAB vs --BLOOD-COAGULATION FACTOR VIII FUSION PROTEIN WITH IMMUNOGLOBULIN G1 , ,-BIS WITH IMMUNOGLOBULIN G1 BLINATUMOMAB vs BOCEPREVIR BLINATUMOMAB vs BOCOCIZUMAB BLINATUMOMAB vs BONIVA

Related Pages

BLINATUMOMAB Full Profile All Therapy non-responder Reports All Drugs Causing Therapy non-responder BLINATUMOMAB Demographics